Paddy 'the Baddy' joins mental health fight - BBC

In the video below, Pimblett shares his personal experience of losing a close friend to suicide and reflects on why speaking openly about mental health is so important. He also talks candidly about his own experience with mental health challenges, saying: “I thought about suicide a couple of times, how I’d do it. To man up, bottle it up and not say anything is just sewn into our being. “There are a lot of lads I know over the past 10 years who’ve taken their own lives and it’s crazy when you think about it, because Scousers are the most happy-go-lucky people in the world. “Every 90 minutes someone takes their own life, that’s just absolutely shocking.”Kick off Conversations with Liverpool FC: Paddy Pimblett on speaking up on World Mental Health DayPimblett shared his story following the launch of the permanent Kicking Off Conversations hub at Anfield, located at the corner of 97 Avenue and run by the club’s official charity LFC Foundation and LFC’s safeguarding team.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.